Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 11/20 | 0.46 |
| ▸ | PDE4A | P27815 | 5/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924755 | 1.00 | PDE4B (0.46) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15580983 | 0.92 | GAA (0.41) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL2031572 | 0.92 | PDE4B (0.46) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL2031569 | 0.92 | PDE4B (0.46) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL14924757 | 0.91 | MAPT (0.41) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15580987 | 0.91 | GAA (0.41) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL14983202 | 0.90 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL30701938 | 0.90 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL15869364 | 0.90 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Dovramilast SCHEMBL29366888 | 0.90 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9387195-B2 | Methods for treating diseases using isoindoline compounds | CELGENE CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140187599-A1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110104144-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | CELGENE CORPORATION (US) | 2011-05-05 | — | — | US | disclosed |
| US-20070155791-A1 | Methods for treating cutaneous lupus using aminoisoindoline compounds | CELGENE CORPORATION | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155791-A1 | Methods for treating cutaneous lupus using aminoisoindoline compounds | SSB, ARG2, ARGLU1 | PDE4B 2118/4885PDE4C 2322/4885PDE4A 2497/4885 |
| US-20110104144-A1 | METHODS FOR TREATING CUTANEOUS LUPUS USING AMINOISOINDOLINE COMPOUNDS | SSB, ARG2, ARGLU1 | PDE4B 2118/4885PDE4C 2322/4885PDE4A 2497/4885 |
| US-20140187599-A1 | METHODS FOR TREATING DISEASES USING ISOINDOLINE COMPOUNDS | UACA, TOP2A, AR | PDE4B 1783/4885PDE4C 1641/4885PDE4A 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.